SURVEY FLIGHT — reconnaissance, not adjudication. A Commander has arrived with an INTENTION, not a question: "I want to cure cancer." That cannot be deliberated. It has no anchor, no bound, and no decision attached. Your job is NOT to answer it, argue it, or solve any part of it. Your job is to MAP THE TERRITORY and hand back the shape of it, so the Commander can choose what is actually worth arguing about.
WHAT A MAP MUST DO. Give the partition, say what the partition is BY (tissue of origin? molecular driver? treatment intent? stage?), and say plainly that it is ONE defensible partition and not THE partition — because a taxonomy feels true merely by being structured, and that is the failure mode of this entire exercise. Where the field genuinely disagrees about how to carve it, say so and name the competing schemes.
WHAT MATTERS MOST, and the reason this flight exists: the map is worthless unless its LEAVES ARE FLYABLE. A leaf is flyable only if a room of six adversarial models could be measurably WRONG about it — something outside the room must be able to contradict the answer: published trial results, a number that must reconcile, a named falsifier. "Research immunotherapy further" is not a leaf. "Checkpoint inhibitors show durable response in under 25 percent of solid tumours and the limiting factor is X rather than Y" is a leaf. Hand back leaves a Commander could press GO on tomorrow.
HONESTY RAILS: no cure is claimed, proposed, or implied. Flag anything at or past your training cutoff as needing verification — every factual claim from this room is audited against primary sources after sealing and overstatement gets published. Where you are uncertain about a number, say uncertain rather than picking one. Prefer being useful over being complete: a small map with flyable leaves beats an exhaustive one with none.
6 models deliberated; a human Commander held the room but did not steer. Sealed 2026-08-12T23:58:11.841Z. Engine lucentfire-roundtable/v1 (live).
The question put to the room
SURVEY FLIGHT — reconnaissance, not adjudication. A Commander has arrived with an INTENTION, not a question: "I want to cure cancer." That cannot be deliberated. It has no anchor, no bound, and no decision attached. Your job is NOT to answer it, argue it, or solve any part of it. Your job is to MAP THE TERRITORY and hand back the shape of it, so the Commander can choose what is actually worth arguing about.
WHAT A MAP MUST DO. Give the partition, say what the partition is BY (tissue of origin? molecular driver? treatment intent? stage?), and say plainly that it is ONE defensible partition and not THE partition — because a taxonomy feels true merely by being structured, and that is the failure mode of this entire exercise. Where the field genuinely disagrees about how to carve it, say so and name the competing schemes.
WHAT MATTERS MOST, and the reason this flight exists: the map is worthless unless its LEAVES ARE FLYABLE. A leaf is flyable only if a room of six adversarial models could be measurably WRONG about it — something outside the room must be able to contradict the answer: published trial results, a number that must reconcile, a named falsifier. "Research immunotherapy further" is not a leaf. "Checkpoint inhibitors show durable response in under 25 percent of solid tumours and the limiting factor is X rather than Y" is a leaf. Hand back leaves a Commander could press GO on tomorrow.
HONESTY RAILS: no cure is claimed, proposed, or implied. Flag anything at or past your training cutoff as needing verification — every factual claim from this room is audited against primary sources after sealing and overstatement gets published. Where you are uncertain about a number, say uncertain rather than picking one. Prefer being useful over being complete: a small map with flyable leaves beats an exhaustive one with none.
What survived
- Distant/metastatic disease carries the overwhelming majority of cancer mortality (~70–90%, exact fraction uncertain) while genuine cures of disseminated disease are confined to a narrow set of lineage-tractable diseases (paediatric ALL, testicular GCT, Hodgkin, APL, some aggressive lymphomas) — direction uncontested by any seat, magnitude contested.
- No approved oncology agent carries metastatic dissemination, dormancy exit, or colonization as its labelled primary mechanism/indication; adjuvant bisphosphonates/denosumab are the sole mechanistic near-exception and are licensed for skeletal-related events, not metastasis prevention — auditable tonight against the FDA/EMA label set.
- Multi-cancer early detection blood tests have shown no cancer-specific mortality reduction; the room's convergence here is cheap and the NHS-Galleri primary readout is past training cutoff and must be verified, not asserted.
Seal (sha-256, single-writer): 3051481462121b840f7e32cc2db138c940f6a54b27329386cf00c7aa1f64ad29
LucentFire